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What is HIV-1? 
• HIV-1 is an epidemic that affects over 34 
million people worldwide. 
• HIV-1 causes disease by attacking CD4 T-cells, 
which are essential to a healthy immune 
system. 
• Viral glycoproteins on the surface on the viral 
envelope are the proteins the virus uses to enter 
and infect these T-cells. 
• These viral glycoproteins consists of two non-
covalently bonded subunits: gp120 and gp41, 
which associate as a heterotrimer.
• gp120 binds to the CD4 cell receptor inducing a 
conformation change exposing the coreceptor
binding site. 
HIV-1 Fusion and Entry
• Once the gp120 subunit binds to the 
coreceptor, the gp41 subunit is exposed and 
undergoes a conformational change, 
unfolding and inserting into the host cell 
membrane. 
• Once the gp41 subunit trimer is inserted, a 
cluster of two trimer prehairpins form. 
• gp41 trimers then fold onto themselves 
creating a hairpin-like six helix bundle. 
• Trimeric hairpins bring the membranes 
together, causing the outer membranes to 
fuse in hemifusion and the inner membrane 
to fuse, completely joining the two.
• The capsid is then free to enter the host cell
Why hasn’t a vaccine been developed yet?
• Because of the nature of these glycoproteins, it is 
very hard to establish a vaccine that will cause 
the production of broadly neutralizing antibodies 
(bnAb)
• Both gp120 and gp41 are highly variable
• Glycosylation on gp120 protects conserved 
epitopes on both gp120 and gp41
• The heavy glycosylation also forms a cage-like 
structure around the gp41 trimer, causing the 
gp41 subunit to be very difficult to access. 
• This protection restricts antibody access to the 
slightly more conserved gp41 region, which 
provides a difficulty when producing a suitable 
vaccine. 
Some strains can be neutralized!
• Even though it is difficult, several 
antibodies have been isolated from 
patients that can neutralize a broad range 
of HIV to a varying degree of success.
• Some of these antibodies are 2F5, 4e10, 
and 10e8, which all target the MPER in 
gp41.
 Other regions in gp120 can also be targeted 
by different neutralizing antibodies
• The most easily neutralized strains are 
tier 1 viruses. These viruses have 
typically been passaged in laboratories for 
easy use.
• Tier 2 and tier 3 viruses are harder to 
neutralize, but are the type of viruses that 
are found in most patients. 
Why can only some strains be neutralized? 
• Our lab focuses mainly on gp41 for several reasons:
 gp41 is more highly conserved and the known bnAbs targeting gp41 are concentrated in a very 
small region (MPER). 
 This small region allows for a minimization of the vaccine candidate size, which can also limit 
the amount of non-neutralizing antibodies produced.
• We would like to understand why tier 2 viruses are more difficult to neutralize with 
gp41-targeting bnAbs than tier 1 viruses.
• The information that will be gathered from this study has the potential to shed light 
on the biological reasons that tier 2 viruses are more resistant than tier 1 viruses. 
• If we are able to understand how these differences prevent neutralizing antibodies 
from binding, we may be able to produce better immunogens able to guide the 
immune system to overcome these resistance-inducing mutations
• For this study, we used MN (tier 1, sensitive) and 6535 (tier 2, resistant) as 
representative viral strains
Original HIV-1 Envelope Sequences
• Previous work identified a region of the gp41 envelope sequence that 
determined whether the strain was sensitive or resistant to neutralization.
• This was accomplished by producing several chimera viruses using 
laboratory techniques such as digestion and ligation. 
• Digestion was done using appropriate restriction sites to cut the original 
sequences into the desired fragments.
• Once the specific fragments were produced, ligation was used to create the 
original chimera viruses, which were used to narrow down the region in 
which the change(s) affecting neutralization resistance is located. 
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• We originally hypothesized that gp120 region should block access to the gp41 region of 
interest. 
• However, we found that gp41 appeared to determine sensitivity and resistance
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• We originally hypothesized that the gp120 region should block access to the gp41 region 
of interest. 
• However, we found that gp41 appeared to determine sensitivity and resistance.
• Therefore, we made additional viruses to identify specific gp41 portions that may be 
involved
Predicted 
Sensitivity
S
S
R
R
Actual 
Sensitivity
S
S
R
R
?
?
Neutralization assay results 
• These two graphs show the neutralization curve 
using the antibodies 2F5 and 10e8. 
• The neutralization sensitive viral strains require 
a much lower amount of antibody for 
neutralization compared to the neutralization 
resistant strains. 
• The viral strain MN.3 (dark blue), and chimeras 
6535mMN (green) and 6535aMN (light blue) show 
neutralization sensitivity to both 2F5 and 10e8 
antibodies
• Because these two chimeras were sensitive, even 
though the gp120 region was from the resistant 
strain, means that gp120 had no effect on the 
neutralization. 
• The viral strains 6535 (red) and the chimera 
6535hMN (purple) both show neutralization 
resistance to both 2F5 and 10e8 antibodies. 
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What do these Results mean? 
gp120 gp41
V2 V3 V5 MPERV4V1
6535mMN: MfeI
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6535hMN: HindIII
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6535aMN: AvrII
S
Region of interest
• There are seven possible differences within this region:
• These point mutants were produced via site directed mutagenesis (SDM) and tested but 
a single mutant was not enough to affect neutralization sensitivity
MN:
6535:
AvrII HindIII
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• In parallel with point mutant production via SDM, additional chimeras were made.
• These additional chimeras were used to verify the hypothesis made by the original 
chimeras, that the region of interest is between the AvrII and HindIII sites. 
• MNh6535 chimera has additional differences in the antibody binding sites that could prevent 
neutralization
Neutralization Assay results
for Additional Chimeras
10E8 2F5
• Mm6hM was resistant as predicted, and Mh6 was sensitive.
• Ma6hM was predicted to be neutralization resistant, but is neutralization sensitive.
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• Because of these results we can hypothesize that there are at least two mutations involved.
o At least one mutation is located in the N-terminal and C-terminal sides of the AvrII site.
• To confirm this hypothesis we looked at the BG505 SOSIP structure from another paper.
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BG505 SOSIP structure:
gp120/gp41 region of interest
• We can use this structure because it includes 
the gp41 MPER region we are interested in.  
o It represents a resistant strain, so we can 
compare it to 6535
• N-terminal= yellow, differences marked in red
• C-terminal= green, differences marked in pink
• V535M (N-terminal)
• May have an effect on interactions between 
env subunits
• L543Q (N-terminal)
• May affect pre-to-post fusion conformation 
change
• F595I (C-terminal)
• May affect conformational changes
V535M
L543Q
F595I
Current Work
MNm6535aMN  (Mm6aM) MfeI AvrII HindIII
F595I
• V535M and L543Q are both located between MfeI and AvrII (red region)
o These two residues are located in the resistant region of the Mm6aM chimera
• We are currently working on placing the F595I mutation within the Mm6aM chimera 
containing the V535M and L543Q changes. 
• After testing this mutant we will be able to determine whether or not the combination of 
these three point mutations is the cause of the change in neutralization sensitivity. 
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Future Applications: Why do we care?
• The information that will be gathered from this study has the potential to shed 
light on why tier 2 viruses are more difficult to neutralize than tier 1 viruses. 
• If we are able to to understand how these differences prevent neutralizing 
antibodies from binding, we may be able to produce better immunogens able to 
guide the immune system to overcome these resistance-inducing mutations
Thank you!
